325 related articles for article (PubMed ID: 26885366)
21. Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells.
Wong J; Choi SYC; Liu R; Xu E; Killam J; Gout PW; Wang Y
Front Cell Infect Microbiol; 2019; 9():25. PubMed ID: 30809511
[TBL] [Abstract][Full Text] [Related]
22. Metastatic Colonization: Escaping Immune Surveillance.
Schaller J; Agudo J
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207601
[TBL] [Abstract][Full Text] [Related]
23. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
Stewart TJ; Smyth MJ
Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
[TBL] [Abstract][Full Text] [Related]
24. Metabolism, LXR/LXR ligands, and tumor immune escape.
Russo V
J Leukoc Biol; 2011 Oct; 90(4):673-9. PubMed ID: 21771899
[TBL] [Abstract][Full Text] [Related]
25. Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy.
Coleman MF; Cozzo AJ; Pfeil AJ; Etigunta SK; Hursting SD
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32244756
[TBL] [Abstract][Full Text] [Related]
26. Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy.
Kim SH; Roszik J; Grimm EA; Ekmekcioglu S
Front Oncol; 2018; 8():67. PubMed ID: 29616189
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects.
Hwang I; Nguyen N
Arch Pharm Res; 2015 Aug; 38(8):1415-33. PubMed ID: 25634101
[TBL] [Abstract][Full Text] [Related]
28. Immunometabolism in cancer: basic mechanisms and new targeting strategy.
Su R; Shao Y; Huang M; Liu D; Yu H; Qiu Y
Cell Death Discov; 2024 May; 10(1):236. PubMed ID: 38755125
[TBL] [Abstract][Full Text] [Related]
29. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.
Martinez-Outschoorn U; Sotgia F; Lisanti MP
Semin Oncol; 2014 Apr; 41(2):195-216. PubMed ID: 24787293
[TBL] [Abstract][Full Text] [Related]
30. Convergence of Cancer Metabolism and Immunity: an Overview.
Dang CV; Kim JW
Biomol Ther (Seoul); 2018 Jan; 26(1):4-9. PubMed ID: 29212301
[TBL] [Abstract][Full Text] [Related]
31. Editorial: Immunometabolic Regulations in Adaptive and Innate Immune Cells Shapes and Re-Directs Host Immunity.
Ho PC; Hess C
Front Immunol; 2017; 8():852. PubMed ID: 28791013
[No Abstract] [Full Text] [Related]
32. Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs.
Whiteside TL; Mandapathil M; Szczepanski M; Szajnik M
Bull Cancer; 2011 Feb; 98(2):E25-31. PubMed ID: 21339097
[TBL] [Abstract][Full Text] [Related]
33. Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells.
Kim SJ; Ha GH; Kim SH; Kang CD
Immunol Invest; 2014; 43(6):517-34. PubMed ID: 24295450
[TBL] [Abstract][Full Text] [Related]
34. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
Kandalaft LE; Motz GT; Duraiswamy J; Coukos G
Cancer Metastasis Rev; 2011 Mar; 30(1):141-51. PubMed ID: 21298574
[TBL] [Abstract][Full Text] [Related]
35. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.
Kwilas AR; Ardiani A; Donahue RN; Aftab DT; Hodge JW
J Transl Med; 2014 Nov; 12():294. PubMed ID: 25388653
[TBL] [Abstract][Full Text] [Related]
36. A Forgotten Corner in Cancer Immunotherapy: The Role of Lipids.
Yu Y; Gao L; Wang Y; Xu B; Maswikiti EP; Li H; Zheng P; Tao P; Xiang L; Gu B; Lucas A; Chen H
Front Oncol; 2021; 11():751086. PubMed ID: 34722305
[TBL] [Abstract][Full Text] [Related]
37. Strategies to relieve immunosuppression in pancreatic cancer.
Schnurr M; Duewell P; Bauer C; Rothenfusser S; Lauber K; Endres S; Kobold S
Immunotherapy; 2015; 7(4):363-76. PubMed ID: 25917628
[TBL] [Abstract][Full Text] [Related]
38. Targeting innate immune pathways in cancer immunotherapy: state of the art.
Mastellos DC
J BUON; 2009 Sep; 14 Suppl 1():S123-30. PubMed ID: 19785054
[TBL] [Abstract][Full Text] [Related]
39. Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.
Payne KK; Bear HD; Manjili MH
Future Oncol; 2014 Aug; 10(10):1779-94. PubMed ID: 25303057
[TBL] [Abstract][Full Text] [Related]
40. A stressful microenvironment: opposing effects of the endoplasmic reticulum stress response in the suppression and enhancement of adaptive tumor immunity.
Rausch MP; Sertil AR
Int Rev Immunol; 2015 Mar; 34(2):104-22. PubMed ID: 25774773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
